Searched over 200M research papers
10 papers analyzed
These studies suggest that long-term statin use is generally safe, reduces mortality and mental health issues in patients with coronary artery disease, and does not increase cancer risk, but persistence with treatment is low and some patients may experience myopathy or adverse effects, especially those with multiple co-morbidities.
20 papers analyzed
Long-term statin use has been associated with improved psychological well-being in patients with coronary artery disease (CAD). A study comparing patients who continuously used statins with those who did not use any cholesterol-lowering drugs found that statin use was linked to a lower risk of abnormal depression scores (OR 0.63), anxiety (OR 0.69), and hostility (OR 0.77). These beneficial effects appear to be independent of the cholesterol-lowering properties of statins.
Statins are highly effective in reducing mortality rates among patients with CAD. Long-term use of statins has been shown to decrease mortality by 24% to 42%, which is comparable to or even greater than the benefits seen with other secondary prevention medications such as aspirin and beta-blockers. In patients with diabetes, the mortality reduction from statins exceeds that achieved with tight glycemic control or other diabetes treatments.
The safety profile of long-term statin use is generally favorable. While there is a modest increase in the risk of new-onset diabetes (about one per thousand patient-years), statins do not adversely affect cognitive function, renal function, or the development of cataracts. Transient increases in liver enzymes occur in a small percentage of patients but are not clinically significant. The risk of serious conditions like rhabdomyolysis is very low, occurring in less than 0.1% of patients. Additionally, long-term statin use does not increase the risk of fatal or nonfatal cancers.
Statins do not have a consistent effect on short-term cognitive function, but long-term use may reduce the incidence of dementia. Studies have shown a 29% reduction in the risk of developing dementia among statin users.
Despite the proven benefits, long-term persistence with statin therapy remains a challenge. Studies have shown that persistence declines significantly over time, with only 42% of patients maintaining adherence after ten years. Factors contributing to poor long-term persistence include older age, lower income, nonwhite race, and less cardiovascular morbidity at the initiation of therapy. Interventions to improve adherence are crucial, especially in the early stages of treatment and among high-risk groups.
Long-term statin use offers substantial benefits in reducing mortality and improving psychological well-being among patients with CAD. The safety profile is generally favorable, with a low risk of serious adverse effects. However, maintaining long-term adherence to statin therapy remains a significant challenge, necessitating targeted interventions to ensure patients continue to reap the benefits of this important medication.
Most relevant research papers on this topic